Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid

Charatcharoenwitthaya, Phunchai; Talwalkar, Jayant A.; Angulo, Paul; Gossard, Andrea A.; Keach, Jill C.; Petz, Janice L.; Jorgensen, Roberta A.; Lindor, Keith D.
February 2010
Digestive Diseases & Sciences;Feb2010, Vol. 55 Issue 2, p476
Academic Journal
journal article
Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 +/- 32 vs. 379 +/- 51), bilirubin (0.8 +/- 0.1 vs. 0.9 +/- 0.1), aspartate aminotransferase (60 +/- 8 vs. 63 +/- 9), and Mayo risk score (3.55 +/- 0.2 vs. 3.62 +/- 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA.


Related Articles

  • The Long-term Beneficial Effects of Ursodeoxycholic Acid in Primary Biliary Cirrhosis are Highly Questionable. Gong Yan; Erik, Christensen; Gluud, Christian // American Journal of Gastroenterology;Feb2007, Vol. 102 Issue 2, p464 

    A letter to the editor is presented in response to article about the long-term effects of ursodeoxycholic acid on people with primary biliary cirrhosis.

  • Response to Licinio et al. Sato, Ken; Hosonuma, Kenichi; Kusano, Motoyasu; Yamada, Masanobu // American Journal of Gastroenterology;Jul2015, Vol. 110 Issue 7, p1086 

    A response from the author of the article "A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafi brate in patients with primary biliary cirrhosis and dyslipidemia" in the 2015 issue is presented.

  • New weapon for primary biliary cirrhosis from Japan. Zeniya, Mikio // Journal of Gastroenterology;2003, Vol. 38 Issue 6, p619 

    Editorial. Studies the use of ursodeoxycholic acid (UDCA) for treating patients with primary biliary cirrhosis in Japan. Symptoms of the disease; Immunological properties of UDCA.

  • Autoimmune Conditions Associated With Primary Biliary Cirrhosis: Response to Ursodeoxycholic Acid Therapy. Zukowski, T. H.; Jorgensen, R. A.; Dickson, E. R.; Lindor, K. D. // American Journal of Gastroenterology;Jun1998, Vol. 93 Issue 6, p958 

    Objectives: A variety of autoimmune conditions occur in association with primary biliary cirrhosis. Among these conditions are sicca syndrome, Raynaud's phenomenon, arthritis, and Hashimoto's thyroiditis. Information is sparse regarding the prevalence and natural history of these conditions when...

  • New directions in primary biliary cirrhosis. Bateson, M.C. // BMJ: British Medical Journal (International Edition);12/8/90, Vol. 301 Issue 6764, p1290 

    Focuses on the management of primary biliary cirrhosis. Indication of liver transplantation; Application of chlorambucil; Observation of the ursodeoxycholic acid.

  • Tissue transplantation.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS107 

    Presents an abstract of the research manuscript `Hepatocellular carcinoma in ursodeoxycholic acid treated primary biliary cirrhosis,' by J. Turner et al.

  • COMMENTARY: Review: Ursodeoxycholic acid does not reduce risk for mortality or liver transplantation in primary biliary cirrhosis. Reichen, Juerg // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p17 

    The author comments on the study which examines the effect of ursodeoxycholic acid (UDCA) in treating patients with primary biliary cirrhosis (PBC). According to the author, the analyzed trials made by the researchers were not supported by adequate treatment duration, considering that the median...

  • Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases? Licinio, Raffaele; Facciorusso, Antonio; Castellaneta, Nicola Maurizio; Di Leo, Alfredo // American Journal of Gastroenterology;Jul2015, Vol. 110 Issue 7, p1086 

    A letter to the editor is presented in response to the article "A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia," by K. Hosonuma and colleagues in the 2015 issue.

  • 原发性胆汁性肝硬化的过去、现在与未来. 朱疆依; 韩 英 // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;Feb2015, Vol. 31 Issue 2, p163 

    Primary biliary cirrhosis (PBC) is a chronic progressive cholestatic liver disease associated with immunity, with unknown etiology and pathogenesis. This article reviews the origin of its name, recent advances in research on PBC, and the prospect of treatment. Ursodeoxycholic acid is considered...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics